Please assess the completion status of the following clinical trial:

Trial Title: S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic or recurrent carcinoma of the esophagus or gastroesophageal junction~  * Squamous cell carcinoma OR~ * Adenocarcinoma~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 100~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 1.5 times upper limit of normal~Cardiovascular:~* No uncontrolled hypertension~* No unstable angina~* No symptomatic congestive heart failure~* No myocardial infarction within the past 6 months~* No serious uncontrolled cardiac arrhythmia~Gastrointestinal:~* No active inflammatory bowel disease~* No significant bowel obstruction~* No chronic diarrhea~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active infection requiring systemic therapy~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 28 days since prior biologic therapy~* No prior biologic therapy for metastatic or recurrent disease~* No concurrent sargramostim (GM-CSF)~* No concurrent immunotherapy for tumor~Chemotherapy:~* At least 28 days since prior chemotherapy~* No prior chemotherapy for metastatic or recurrent disease~* No prior gemcitabine or irinotecan~* Prior adjuvant or neoadjuvant chemotherapy at time of initial diagnosis of localized disease allowed~* No other concurrent chemotherapy for tumor~Endocrine therapy:~* See Disease Characteristics~* At least 28 days since prior endocrine therapy~* No prior endocrine therapy for metastatic or recurrent disease~* No concurrent hormonal therapy for tumor~Radiotherapy:~* At least 28 days since prior radiotherapy~* No prior radiotherapy for metastatic or recurrent disease~* Prior adjuvant or neoadjuvant radiotherapy at time of initial diagnosis of localized disease allowed~* No concurrent radiotherapy for tumor~Surgery:~* Prior thoraco-abdominal surgery allowed~* At least 3 weeks since prior surgery and recovered~Other:~* No other concurrent anti-cancer therapy for tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Irinotecan (Type: EXPERIMENTAL): Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days

Based on this trial design, predict the completion outcome and termination type (if applicable).